Adap­ti­m­mune trims pipeline, un­veils plans to lay off 25%+ of em­ploy­ees amid sweet­ened ES­MO da­ta

Adap­ti­m­mune has a bit­ter pill to swal­low af­ter GSK axed its part­ner­ship in late Oc­to­ber, com­ing in the form of a re­or­ga­ni­za­tion and bud­get cuts.

The T cell-fo­cused biotech an­nounced the news Tues­day morn­ing at the start of its Q3 earn­ings call, cit­ing a need to pri­or­i­tize cer­tain pro­grams. CEO Adri­an Raw­cliffe said on the call, af­ter talk­ing about hav­ing its PRAME pro­gram back un­der com­pa­ny con­trol, “We are well placed to de­liv­er high val­ue prod­ucts with two of the most broad­ly ex­pressed, well char­ac­ter­ized and val­i­dat­ed TCR T cell tar­gets in the sol­id tu­mor field.”

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER